Skip to main content

Enlivex Ltd.

corporate_fare Company Profile

Enlivex Ltd.

ENLV·NASDAQ·Crypto Assets·CIK 0001596812

Enlivex Ltd. is a company incorporated under the laws of the State of Israel. The company was originally incorporated as Bioblast Pharma Ltd. on January 22, 2012. On March 26, 2019, Bioblast Pharma Ltd. merged with Enlivex R&D (formerly Enlivex Therapeutics Ltd.), with Enlivex R&D becoming a wholly owned subsidiary of Bioblast. Following the merger, Bioblast Pharma Ltd. changed its name to Enlivex Therapeutics Ltd. In February 2026, the company changed its name to Enlivex Ltd. Its primary operating subsidiary, Enlivex R&D, was initially incorporated as Tolarex Ltd. in September 2005 in Israel. In February 2010, Tolarex Ltd. changed its name to Enlivex Therapeutics Ltd., and after the merger, to Enlivex Therapeutics R&D Ltd. In June 2021, Enlivex Therapeutics RDO Ltd. was established in Israel as a wholly owned subsidiary. The company also has a wholly owned U.S. subsidiary, Enlivex Therapeutics Inc., incorporated in Delaware. Enlivex Ltd.'s principal executive offices are located at 14 Einstein Street, Ness Ziona, Israel 7403618. The company's capital expenditures for the three years ended December 31, 2025, 2024, and 2023 were insignificant.

Enlivex Ltd. (NASDAQ:ENLV) is a publicly traded company in the Crypto Assets sector. Wiseek has independently scored 44 items for ENLV at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for ENLV spans 6-K, 6-K/A, F-3.

Recent high-impact activity:

  • Enlivex Clears DSMB Safety Review in Phase IIb Knee Osteoarthritis Trial
  • Enlivex Closes First $500K Tranche of $7.5M Offering; Remaining $7M Hinges on Nasdaq Listing
  • Enlivex Calls Dec 4 Vote to Lift Authorized Shares from 9.9M to 95M
  • Enlivex Raises $7.5M at 10.5% Premium With Warrants Attached
  • Enlivex Prices $7.5M Staged Registered Direct Offering at 10.5% Premium, With Warrants and 5% Revenue Share

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
$1.24B
Diluted EPS
$25.48
Op. Cash Flow
-$10.42M
Free Cash Flow
-$10.48M
Operating Income
-$15.03M
Cash & Equivalents
$1.89M
Debt / Equity
0.00×
Shares Outstanding
237.38M sh
Source: 20-F · filed 2026-03-25 · accession 0001213900-26-033857

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 22,618 shares in ENLV as of the October 30, 2026 settlement, a 85.8% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 46.8% of ENLV volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)22,618 shares as of October 30, 2026
Change vs prior period▼ 85.8%
Days to cover1.00 at avg daily volume of 48,253
Daily short volume (FINRA facilities)46.8% of 8,017 shares on November 20, 2026
5-day average short volume54.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for ENLV, detected from its recent SEC filings · based on capital-structure filings through 2026-11-17.

1 recent capital raise1 shelf registrationreverse split

Additional Share Registration · Conversion Price Far Above Market

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

ENLV files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with E →
$1.07 +1.90% today
52-week range · as of 2026-11-18 $1 – $434.4
Market cap
$1.61M
Volume
41K (0.9× avg)
3-mo avg 45.7K
Live data · 2026-11-21 19:37 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ENLV - Latest Insights

ENLV
Nov 18, 2026, 8:01 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.18
Real-time Price: $1.07 info
Change: -$0.110 (-9%) info
Market Cap: $1.609M info
ENLV
Nov 17, 2026, 4:50 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.15
Real-time Price: $1.07 info
Change: -$0.080 (-7%) info
Market Cap: $1.609M info
ENLV
Nov 17, 2026, 4:40 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.15
Real-time Price: $1.07 info
Change: -$0.080 (-7%) info
Market Cap: $1.609M info
ENLV
Nov 16, 2026, 8:42 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1.08
Real-time Price: $1.07 info
Change: -$0.010 (-0.93%) info
Market Cap: $1.609M info
ENLV
Nov 16, 2026, 8:00 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.06
Real-time Price: $1.07 info
Change: +$0.010 (+0.94%) info
Market Cap: $1.609M info
ENLV
Nov 02, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Updated Nov 2, 8:03 AM ET — The 12-month data will be presented at ACR Convergence on November 8, 2026, and Enlivex guides Phase IIb topline data in the same populatio…
Price at Filing: $1.90
Real-time Price: $1.07 info
Change: -$0.830 (-44%) info
Market Cap: $1.609M info
ENLV
Oct 27, 2026, 8:59 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $0.1722
Real-time Price: $1.07 info
Change: Reverse Stock Split info
Market Cap: $1.609M info
ENLV
Oct 27, 2026, 8:01 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.1722
Real-time Price: $1.07 info
Change: Reverse Stock Split info
Market Cap: $1.609M info
ENLV
Oct 22, 2026, 5:17 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.59
Real-time Price: $1.07 info
Change: Reverse Stock Split info
Market Cap: $1.609M info
ENLV
Oct 19, 2026, 8:18 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.215914
Real-time Price: $1.07 info
Change: Reverse Stock Split info
Market Cap: $1.609M info
ENLV
Oct 02, 2026, 4:15 PM EDT
Filing Type: 6-K/A
Importance Score:
8
Price at Filing: $0.3903
Real-time Price: $1.07 info
Change: Reverse Stock Split info
Market Cap: $1.609M info
ENLV
Sep 29, 2026, 5:10 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.4956
Real-time Price: $1.07 info
Change: Reverse Stock Split info
Market Cap: $1.609M info
ENLV
Sep 25, 2026, 4:15 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.5938
Real-time Price: $1.07 info
Change: Reverse Stock Split info
Market Cap: $1.609M info
ENLV
Sep 22, 2026, 8:02 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.7005
Real-time Price: $1.07 info
Change: Reverse Stock Split info
Market Cap: $1.609M info
ENLV
Aug 11, 2026, 4:15 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.92
Real-time Price: $1.07 info
Change: Reverse Stock Split info
Market Cap: $1.609M info
ENLV
Aug 06, 2026, 4:43 PM EDT
Filing Type: F-3
Importance Score:
7
Price at Filing: $1.94
Real-time Price: $1.07 info
Change: Reverse Stock Split info
Market Cap: $1.609M info
ENLV
Jul 30, 2026, 8:02 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.21
Real-time Price: $1.07 info
Change: Reverse Stock Split info
Market Cap: $1.609M info
ENLV
Jul 28, 2026, 4:40 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.30
Real-time Price: $1.07 info
Change: Reverse Stock Split info
Market Cap: $1.609M info
ENLV
Jul 28, 2026, 8:02 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.47
Real-time Price: $1.07 info
Change: Reverse Stock Split info
Market Cap: $1.609M info
ENLV
Jul 28, 2026, 8:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $3.47
Real-time Price: $1.07 info
Change: Reverse Stock Split info
Market Cap: $1.609M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets